Please login to the form below

Not currently logged in
Email:
Password:

lasmiditan

This page shows the latest lasmiditan news and features for those working in and with pharma, biotech and healthcare.

Lilly set to head to regulators with CGRP migraine drug

Lilly set to head to regulators with CGRP migraine drug

Lilly recently added to its galcanezumab programme in migraine by buying CoLucid and its lead drug lasmiditan, an oral serotonin 5-HT 1F agonist that is due to be filed for

Latest news

  • Lilly to buy migraine drug developer CoLucid for $960m Lilly to buy migraine drug developer CoLucid for $960m

    Lilly to buy migraine drug developer CoLucid for $960m. Deal revolves around lasmiditan, which the firm out-licensed in 2005. ... Lasmiditan's different mechanism means it could become the first drug that works without vasoconstriction, according to Lilly

  • Migraine drugs' headache Migraine drugs' headache

    CoLucid Pharmaceuticals is developing lasmiditan, which specifically agonises the serotonin 1F receptor.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics